title: Significant role of Fas ligand-binding but defective Fas receptor (CD95) in lymph node hyperplasia composed of abnormal double-negative T cells.
abstract: The functional differences between two mutations of the Fas (CD95) locus, Faslpr (lpr) and Faslprcg (lprcg), were investigated using bone marrow (BM) transplantation on the C3H mouse background. Both lpr/lpr and lprcg/lprcg BM transferred caused lymph node (LN) hyperplasia in lpr/+ and lprcg/+ recipients, although it was clearly smaller than that in lpr/lpr and lprcg/lprcg recipients of lpr/lpr and lprcg/lprcg BM. In addition, both BM induced significantly larger LN hyperplasia in lprcg/+ than lpr/+ recipients. Appearance of CD4- CD8-[double negative (DN)] T cells in the periphery is the most consistent phenotype of Fas mutations. Importantly, the proportion of DN T cells was higher in larger LN hyperplasia in the order of lpr/+, lprcg/+ and lpr/lpr or lprcg/lprcg recipients. On the other hand, both lpr/lpr and lprcg/lprcg BM transferred into wild-type (+/+) mice caused marked LN atrophy. The former, but not the latter, induced wasting syndrome. Faslg1d (gld)-homozygous lpr/lpr BM transferred into +/+ mice elicited LN hyperplasia of the same extent as that in lpr/lpr mice transferred with lpr/lpr BM, but not wasting syndrome. Taken together with the fact that DN T cells massively express Fas ligand (FasL), this study implied that FasL overexpressed on DN cells may be involved in the accumulation of DN T cells in LN, LN atrophy and wasting syndrome, and that lprcg Fas, which can bind to Fas ligand but not transduce apoptosis signal into cells, may modulate these pathological conditions by interfering with the binding of FasL to Fas.
authors.affiliation: Laboratory Animal Research Center and Department of Surgery, Institute of Medical Science, University of Tokyo, Shirokanedai, Minato-ku, Tokyo, Metropolitan Institute of Medical Science, Honkomagome, Bunkyo-ku, Tokyo, Japan. atmatsu@oregano.ocn.ne.jp
authors.forename: Akio
authors.initials: A
authors.lastname: Matsuzawa
authors.forename: Motomu
authors.initials: M
authors.lastname: Shimizu
authors.forename: Yasutaka
authors.initials: Y
authors.lastname: Takeda
authors.forename: Hisashi
authors.initials: H
authors.lastname: Nagase
authors.forename: Kazutoshi
authors.initials: K
authors.lastname: Sayama
authors.forename: Mikio
authors.initials: M
authors.lastname: Kimura
mesh_terms: D000818:Animals; D000974:Antibodies, Antinuclear / Q000032:analysis; D001667:Binding, Competitive; D016026:Bone Marrow Transplantation; D053222:Fas Ligand Protein; D005260:Female; D006965:Hyperplasia / Q000276:immunology; D008198:Lymph Nodes / Q000473:pathology*; D008297:Male; D008562:Membrane Glycoproteins / Q000276:immunology*; D051379:Mice; D008809:Mice, Inbred C3H; D009154:Mutation; D016176:T-Lymphocyte Subsets / Q000276:immunology*; D019282:Wasting Syndrome / Q000276:immunology; D019014:fas Receptor / Q000235:genetics / Q000276:immunology*
chemical_list: D000974:Antibodies, Antinuclear; D053222:Fas Ligand Protein; C505658:Fasl protein, mouse; D008562:Membrane Glycoproteins; D019014:fas Receptor